Business Articles

Medical billing of DMEPOS claims is difficult enough under the best circumstances. With all the different items that can be billed and the various require

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

ments for each of them, difficult becomes an exercise in near futility. In this installment, we continue our review with one of the most massive CMNs in e

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

ectronic transmission of claims. We'll cover the GU0 record continuing with field number 26. This is where things get so complicated the each field becom

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

s more and more difficult just to explain.

GU0 field 26, position 112, is Reply ALN L01 N01. This is the first of many fields that refer back to a specif

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

c question on a specific CMN, kind of like a mapped grid. Because there are so many CMNs and this GUO record has to accommodate all of them that apply, th

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

ese fields are given generic descriptions that refer back to a specific form location as described in the manual. This particular field refers back to the

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

first question on any DMERC certification requiring a one position response. The forms supported by this field are generic certifications, lymphedema pump

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

and Osteogenesis stimulators. The form numbers are 01, 02, 04, 06, 07, 08, 09 and 10. The questions supported for the various forms are 1, 4, 6 and 7.

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

he valid responses are Y, N or D. Refer to your manual for the specific form names and questions.

GU0 field 27, position 113, is Reply ALN L01 N02. This

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

is the response to the second question on any DMERC certification requiring a one position response. The forms supported are 02, 04, 06 and 07 for respon

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

es Y, N or D. The form supported for only responses Y or N is 08. Forms 01, 03, 05, 09 and 10 are reserved for future use. These forms also cover generi

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

CMNs, lymphedema pumps and osteogenesis stimulators.

GU0 field 28, position 114, is Reply ALN L01 N03. This is the response to the third question on any

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

DMERC certification requiring a one position response. The forms supported are 01, 02, 04 and 07 for responses Y, N or D. For form 06, the valid response

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

s are 1, 2, 3, 4, or 5. Forms 03 and 09 are reserved for future use. The valid responses for form 10 is 1, 3 or 7. These forms also cover generic CMNs,

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

ymphedema pumps and osteogenesis stimulators.

GU0 field 29, position 115, is Reply ALN L01 N04. This is the response to the fourth question on any DMERC

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

ertification requiring a one position response. The forms supported are 01, 02, 04, 06 and 07 for responses Y, N or D. Forms 03, 09 and 10 are reserved f

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

r future use. These forms also cover generic CMNs, lymphedema pumps and osteogenesis stimulators.

GU0 field 30, position 116, is Reply ALN L01 N05. This

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

is the response to the fifth question on any DMERC certification requiring a one position response. The forms supported are 01, 02, 04, 06 and 07 for res

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

onses Y, N or D. For form 10, the valid response is either Y or N. Forms 03 and 09 are reserved for future use. These forms also cover generic CMNs, lym

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

hedema pumps and osteogenesis stimulators.

In our next installment of medical billing, we'll continue with the GU0 record, picking up with field number 31

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.businessarticles.org.ua/article/2254/businessarticles-Medical-Billing--GU0-Record-Fields-26-Through-30.html">Medical Billing - GU0 Record Fields 26 Through 30</a>

BB link (for phorums):
[url=http://www.businessarticles.org.ua/article/2254/businessarticles-Medical-Billing--GU0-Record-Fields-26-Through-30.html]Medical Billing - GU0 Record Fields 26 Through 30[/url]

Is a state-wide Mobile Oil Change Business viable for the West Virginia Market? Recently we were asked to consult an upstart entrepreneur interested in the mobile oil changing industry sub-sector and looking to target his state of West Virginia. Are there any such businesses now like this in the Great State of West Virginia?

Every project - large or small - needs a vision outlining what success looks like and how the project team will make success a reality. Here are four steps to creating that successful project vision.

An entrepreneur may expand and diversify his business by opening branches that are geographically separated from the central enterprise. Branches function independently, but remain part of the central organisation. The concept branch implies that there is a central organisation with a head office.

Tags

Links

Business Articles - Medical Billing - GU0 Record Fields 26 Through 30

Related Articles: